Alzheimers
-
Alzheimer’s Amyloid Beta Explained: How Plaques Form and Two New Blood Tests Detect Them
NEW YORK, July 16 — For the millions of families touched by Alzheimer’s disease, the science can feel impossibly distant. But behind…
-
New Alzheimer’s Drug Kisunla Carries Significant Brain Risk Factors
The U.S. Food and Drug Administration approved Eli Lilly’s monoclonal antibody donanemab, marketed as Kisunla, on July 15, 2024. The drug is…
-
New Alzheimer’s Drug Lecanemab Slows Cognitive Decline in Trial
WASHINGTON, July 14 — For the millions of American families watching a loved one slowly lose their memories, the arrival of lecanemab…
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992
LONDON, July 10 — John Hardy, the British geneticist and neuroscientist who first proposed that amyloid-beta accumulation is the primary cause of…
-
Alzheimer’s Drug Lecanemab Slows Cognitive Decline 27% in Trial
MANILA, July 10 — For millions of families across Asia and around the world, the shadow of Alzheimer’s disease has long been…
-
Alzheimer’s in America: 6.9 million patients and $360 billion in care costs in 2024
WASHINGTON, July 8 — The numbers arrive with the cold weight of an epidemic that refuses to recede. By 2024, an estimated…
-
Lecanemab and Donanemab: Biology of Amyloid-Targeting Drugs
ISLAMABAD, July 8 — For decades, the sticky clumps of protein that build up in the brains of Alzheimer’s patients have been…
-
Two Antibody Drugs Now Slow Early Alzheimer’s Decline, With Brain-Swelling Risks
WASHINGTON — For the millions of American families touched by Alzheimer’s disease, the past few years have brought something that once felt…
-
Tire chemical linked to new Alzheimer’s risk factor
SAN FRANCISCO — A study published in 2024 in the journal Environmental Health Perspectives has identified a chemical, 6PPD-quinone, as a potential…
-
Mouse Study Links Alcohol Flush Gene to Alzheimer’s-Related Brain Changes
For millions of people, a glass of wine brings an immediate, unmistakable flush. That red face has long been dismissed as a…
-
Omega-3 health update after major new study into claims
LOS ANGELES, June 30 — 365 older adults. Two years. Zero measurable brain benefit from fish oil supplements. That is the bottom…
-
High-Dose Fish Oil Shows No Cognitive Benefit in Older Adults at Alzheimer’s Risk
LOS ANGELES — For two years, researchers tracked 365 older adults who took high doses of fish oil. The result, published by…
-
Sunlight could be crucial to preventing dementia, study finds
LONDON, June 27 — Getting enough sunlight could be crucial in preventing dementia, a study has found. People who spend, on average,…
-
Brain Changes Precede Alzheimer’s Plaques by Years, and Memory Awareness Fades Before Dementia
The clock on dementia starts ticking long before the first forgotten name. New research confirms what many in the longevity field have…
-
Oral Arginine Cuts Amyloid Buildup in Fly and Mouse Models of Alzheimer’s
TOKYO, June 6, 2026 — infopulsetoday.com — Researchers in Japan have made a promising discovery in the fight against Alzheimer’s disease, reporting…
-
Scientists Find Molecular Switch Locking Alzheimer’s Inflammation On
LA JOLLA, June 5 — Researchers at Scripps Research have made a significant discovery in understanding the molecular mechanism behind the chronic…
-
Scripps Research Finds STING Protein Fuels Alzheimer’s Inflammation
LA JOLLA, June 5 — A research team at Scripps Research has identified a specific biochemical alteration that drives chronic inflammation in…
-
Scripps Team Finds Protein Switch Behind Alzheimer’s Brain Inflammation in Mice
A specific chemical alteration to a single protein may be the mechanism that sustains destructive brain inflammation in Alzheimer’s disease, according to…
-
FDA Approves Eli Lilly Alzheimer’s Drug Kisunla Amid Safety Concerns
July 18, 2024 — infopulsetoday.com — The path to the FDA’s July 15 approval of donanemab was paved with controversy, clinical risk,…
-
FDA Approves Eli Lilly’s Donanemab for Early Symptomatic Alzheimer Disease
On July 15, 2024, the US Food and Drug Administration (FDA) approved donanemab, a monoclonal antibody developed by Eli Lilly and Company,…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
How Dynasty Trusts Preserve Wealth for a Century Using GST Exemptions
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
How Major Medical Centers Partner With Tech Firms for Next-Gen Proton Therapy
-
FDA Denies Approval for Summit Therapeutics’ Ivonescimab in Lung Cancer
-
How will the next era of precision thoracic oncology change treatment choices for lung‑cancer patients?
-
FDA Approval Moves Astellas’ Padcev Into Curative Bladder Cancer Setting
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
Navigating 7% Mortgage Rates: Strategies for Buying a Home Now
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992




















